# Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML)

> **NCT01160354** · PHASE1,PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 22 (actual)

## Conditions studied

- Acute Myelogenous Leukemia

## Interventions

- **DRUG:** Plerixafor
- **DRUG:** Clofarabine

## Key facts

- **NCT ID:** NCT01160354
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-08
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Slow Accrual
- **Last updated:** 2019-08-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01160354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01160354, "Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01160354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*